World Trade Systems PLC (WTS) is a UK company listed on the main market operated by the London Stock Exchange (LSE) since 1988. Having undertaken limited trading activity for a number of years, 2016 saw WTS begin a new chapter following the appointment of Vice Chairman Shao Chen in February bringing with him 10 years of experience as an entrepreneur in biotechnology and the healthcare industry. Shao Chen was determined to bring WTS to life after 8 years of suspension of trading in its shares. In June 2016 WTS incorporated its wholly-owned subsidiary Shimao (Suzhou) Biotechnology Co. Ltd (“WTS China”) and commenced trading as a healthfood product company on 14th July 2016. 

With the help of Shao Chen and a new team of experienced executives and managers, WTS China has become fully licensed as a wholly foreign owned enterprise (“WFOE”) to engage in the manufacture and sale of bio-technology based healthfood products. But this is just the beginning of WTS’s overall strategic plan. Through domestic and cross-border mergers and acquisitions and other forms of cooperative ventures,  the Company intends to leverage WTS China’s knowledge and resources in R&D, supply chain management, sales channels and product branding, to further develop its product base, and produce and sell an expanded portfolio of healthcare products, not only to the Chinese market, but also in the rest of Asia, Europe and other appropriate markets. In this way, WTS aims to become a leading international group specialising in the global health food market with a continuously developing variety of trusted and respected products and brands.

In the following pages of this Annual Report shareholders will find a full description of WTS China’s present business activities and the results of its first 6 months of operation. We will also present the details of WTS’s vision for the group as a whole and the strategy for its implementation in the coming years.